Chemoinformaics analysis of (3e)-2,6-dimethylhepta-3,5-dien-2-ol
| Molecular Weight | 140.226 | nRot | 2 |
| Heavy Atom Molecular Weight | 124.098 | nRig | 2 |
| Exact Molecular Weight | 140.12 | nRing | 0 |
| Solubility: LogS | -1.586 | nHRing | 0 |
| Solubility: LogP | 2.315 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 26 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 10 | No. of Aromatic Carbocycles | 0 |
| nHetero | 1 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 16 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 9 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 1 | No. of Arom Bond | 0 |
| nHA | 1 | APOL | 26.5007 |
| nHD | 1 | BPOL | 16.0513 |
| QED | 0.583 |
| Synth | 3.113 |
| Natural Product Likeliness | 2.898 |
| NR-PPAR-gamma | 0.003 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0 |
| Pgp-sub | 0.01 |
| HIA | 0.005 |
| CACO-2 | -4.171 |
| MDCK | 0.0000221 |
| BBB | 0.987 |
| PPB | 0.565997 |
| VDSS | 1.521 |
| FU | 0.543631 |
| CYP1A2-inh | 0.108 |
| CYP1A2-sub | 0.484 |
| CYP2c19-inh | 0.076 |
| CYP2c19-sub | 0.896 |
| CYP2c9-inh | 0.024 |
| CYP2c9-sub | 0.726 |
| CYP2d6-inh | 0.162 |
| CYP2d6-sub | 0.738 |
| CYP3a4-inh | 0.015 |
| CYP3a4-sub | 0.321 |
| CL | 7.757 |
| T12 | 0.801 |
| hERG | 0.016 |
| Ames | 0.006 |
| ROA | 0.051 |
| SkinSen | 0.946 |
| Carcinogencity | 0.655 |
| EI | 0.992 |
| Respiratory | 0.235 |
| NR-Aromatase | 0.005 |
| Antiviral | No |
| Prediction | 0.948614 |